ロード中...
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
BACKGROUND: There is lack of evidence about systemic treatment of pseudomyxoma peritonei (PMP) relapsing after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. There is also lack of biomarkers able to predict outcomes beyond known clinical and pathological prognostic features. ME...
保存先:
| 出版年: | J Transl Med |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2016
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4859944/ https://ncbi.nlm.nih.gov/pubmed/27154293 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-016-0877-x |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|